טוען...
Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non‐small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoin...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wiley-Blackwell
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313266/ https://ncbi.nlm.nih.gov/pubmed/27534574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0189 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|